Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme system in gastric parietal cells.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES).
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing erosive esophagitis:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Pathological hypersecretory conditions (ZES):** 40 mg orally or intravenously twice daily. Doses may be increased to 80 mg intravenously or orally twice daily based on clinical response. Doses exceeding 80 mg daily should be given intravenously.
## Pediatric Dosing
* **GERD and erosive esophagitis (patients 5 to 16 years):**
* **Erosive esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **GERD:** 20 mg orally once daily for up to 8 weeks.
* **Note:** Safety and efficacy for other indications or in younger pediatric patients are not established.
## Dose Adjustments
* **Hepatic impairment:** Maximum daily dose of 40 mg orally or intravenously.
* **Renal impairment:** No dose adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
* **Serious:** *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia (especially with concomitant diuretic use or long-term use), vitamin B12 deficiency, lupus erythematosus (cutaneous and systemic).
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, iron salts, mycophenolate mofetil. Pantoprazole can decrease their absorption.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole may affect the metabolism of drugs like clopidogrel, though clinical significance is debated.
## Monitoring
* Assess for signs and symptoms of *C. difficile*-associated diarrhea.
* Monitor serum magnesium levels, particularly in patients on long-term therapy or with concomitant diuretic use.
* Consider monitoring vitamin B12 levels with long-term therapy.
* Monitor bone mineral density in patients at risk for osteoporosis.
## Clinical Pearls
* Pantoprazole is generally given 30-60 minutes before a meal.
* IV administration is typically reserved for situations where oral intake is not possible or feasible.
* Long-term PPI use (greater than 1 year) is associated with increased risk of fractures, *C. difficile* infection, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary.
* For patients on multiple medications, consider potential drug interactions, especially those requiring acidic gastric pH for absorption.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your healthcare provider for specific patient care decisions.
